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Serum after traumatic brain injury increases proliferation and
supports expression of osteoblast markers in muscle cells
Abstract
BACKGROUND: Traumatic brain injury is associated with an increased rate of heterotopic ossification
within skeletal muscle, possibly as a result of humoral factors. In this study, we investigated whether
cells from skeletal muscle adopt an osteoblastic phenotype in response to serum from patients with
traumatic brain injury.
METHODS: Serum was collected from thirteen patients with severe traumatic brain injury, fourteen
patients with a long-bone fracture, and ten control subjects. Primary cultures of skeletal muscle cells
isolated from patients undergoing orthopaedic surgery were performed and characterized with use of
immunofluorescence microscopy, reverse transcription-polymerase chain reaction, and Western blot
analysis. Proliferation and osteoblastic differentiation were assessed with use of commercial cell assays,
Western blot analysis (for Osterix protein), and the Villanueva bone stain.
RESULTS: All serum-treated cell populations expressed the osteoblast marker Osterix after one week in
culture. Cells treated with serum from all study groups in mineralization medium had increased alkaline
phosphatase activity and mineralized nodules within the mesenchymal cell subpopulation after three
weeks in culture. Serum from patients with traumatic brain injury induced a significant increase (p =
0.02) in the rate of proliferation of primary skeletal muscle cells (1.87 [95% confidence interval, 1.66 to
2.09]) compared with the rate induced by serum from patients with a fracture (1.42 [95% confidence
interval, 1.21 to 1.58]) or by serum from controls (1.35 [95% confidence interval, 1.15 to 1.54]).
CONCLUSIONS: Human serum supports the osteoblastic differentiation of cells derived from human
skeletal muscle, and serum from patients with severe traumatic brain injury accelerates proliferation of
these cells. These findings suggest the early presence of humoral factors following traumatic brain
injury that stimulate the expansion of mesenchymal cells and osteoprogenitors within skeletal muscle.
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The Journal of Bone and Joint Surgery
Serum After Traumatic Brain Injury Increases
Proliferation and Supports Expression of
Osteoblast Markers in Muscle Cells
By Dieter Cadosch, MD, PhDc, Andrew M. Toffoli, MD, Oliver P. Gautschi, MD, So¨nke P. Frey, MD,
Rene´ Zellweger, MD, Allan P. Skirving, MD, and Luis Filgueira, MD
Investigation performed at the University of Western Australia, Crawley, and the Royal Perth Hospital, Perth, Western Australia, Australia
Background: Traumatic brain injury is associated with an increased rate of heterotopic ossification within skeletal
muscle, possibly as a result of humoral factors. In this study, we investigated whether cells from skeletal muscle adopt
an osteoblastic phenotype in response to serum from patients with traumatic brain injury.
Methods: Serum was collected from thirteen patients with severe traumatic brain injury, fourteen patients with a long-
bone fracture, and ten control subjects. Primary cultures of skeletal muscle cells isolated from patients undergoing
orthopaedic surgery were performed and characterized with use of immunofluorescence microscopy, reverse transcription-
polymerase chain reaction, and Western blot analysis. Proliferation and osteoblastic differentiation were assessed with
use of commercial cell assays, Western blot analysis (for Osterix protein), and the Villanueva bone stain.
Results: All serum-treated cell populations expressed the osteoblast marker Osterix after one week in culture. Cells
treated with serum from all study groups in mineralization medium had increased alkaline phosphatase activity and
mineralized nodules within the mesenchymal cell subpopulation after three weeks in culture. Serum from patients with
traumatic brain injury induced a significant increase (p = 0.02) in the rate of proliferation of primary skeletal muscle cells
(1.87 [95% confidence interval, 1.66 to 2.09]) compared with the rate induced by serum from patients with a fracture
(1.42 [95% confidence interval, 1.21 to 1.58]) or by serum from controls (1.35 [95% confidence interval, 1.15 to 1.54]).
Conclusions: Human serum supports the osteoblastic differentiation of cells derived from human skeletal muscle, and
serum from patients with severe traumatic brain injury accelerates proliferation of these cells. These findings suggest the
early presence of humoral factors following traumatic brain injury that stimulate the expansion of mesenchymal cells and
osteoprogenitors within skeletal muscle.
Clinical Relevance: A better understanding of the pathophysiological mechanisms that lead to the formation of het-
erotopic ossification in patients with a traumatic brain injury may be helpful in the prevention and treatment of this
complication.
T
he incidence of heterotopic ossification after severe
traumatic brain injury is between 11% and 25%1.
Heterotopic ossification is characterized by the forma-
tion of lamellar bone at ectopic sites, such as skeletal muscle
and connective tissue surrounding joints2-4. Histologically and
radiographically, heterotopic bone resembles normal mature
bone and is distinguished from simple calcification by the
nature of its osteoblastic capacity5,6. It can cause pain and re-
duce the range of joint motion, and, at worst, it can result in
complete ankylosis (in 10% to 16% of cases)7-9.
Heterotopic ossification requires stimulation of mesen-
chymal cell recruitment, proliferation, and differentiation,
followed by osteoprogenitor maturation and osteoblast acti-
vation10. Several groups of investigators, including ours, have
suggested the importance of humoral factors in the cascade
of events leading to heterotopic ossification on the basis of in
vitro studies demonstrating the mitogenic and osteogenic ef-
fects of serum from subjects who had undergone trauma to the
central nervous system11-16. These investigators used models of
osteoblasts, mesenchymal stem cells, and fibroblasts, but none
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reviewed the effect of serum from patients with traumatic
brain injury on cells derived from skeletal muscle.
Heterotopic ossification occurs in skeletal muscle more
frequently than it does in soft tissues17-19, presumably because
of skeletal muscle’s blood supply and the presence of stem
cells capable of osteogenic differentiation20. Cells isolated from
adult human skeletal muscle have been shown to be able to
differentiate into osteoblastic cells in vitro21,22 and to form new
bone when reimplanted into animals23-25.
In the present in vitro study, we investigated the effects of
serum from patients with traumatic brain injury on cells ex-
tracted from human skeletal muscle in an attempt to reveal the
processes underlying heterotopic ossification.
Materials and Methods
Patients and Specimen Collection
Ethics approval was granted by the Royal Perth HospitalHuman Research Ethics Committee, and all patients or
their next of kin gave informed consent. Skeletal muscle was
obtained from thirty-eight consecutive patients without known
myopathy or a connective-tissue disorder who were under-
going orthopaedic surgery. Specimens were obtained from
muscle in the lower limb (twenty-two samples) or the upper
limb (fifteen samples). A sample of the rectus abdominis was
excised from one patient. The mean age of the muscle donors
was 37.6 years (range, eighteen to eighty years).
Serum was collected from twenty-seven consecutive in-
dividuals recruited from the Royal Perth Hospital, Perth,
Western Australia. Thirteen patients with an isolated severe
brain injury were treated at our level-I trauma center according
to the Advanced Trauma Life Support guidelines26. After pri-
mary diagnostic and therapeutic management, the patients
were transferred to the intensive care unit. Fourteen patients
with an isolated long-bone shaft fracture without a traumatic
brain injury were also recruited. Ten healthy volunteers were
recruited as control subjects. The overall mean age of the blood
donors in the study was 33.8 years (range, eighteen to seventy-
two years), and the mean ages did not differ significantly among
the study groups (p > 0.05).
On admission, all patients with a traumatic brain injury
were evaluated with the Glasgow Coma Scale27 and Abbrevi-
ated Injury Scale score28. The type and extent of the hemor-
rhagic central nervous system lesion or diffuse cerebral edema
were determined with computed axial tomography. The eli-
gibility criteria for the patients with a traumatic brain injury
were an isolated severe traumatic brain injury, a Glasgow
Coma Scale score of £8 points, and an Abbreviated Injury Scale
score of ‡2 points. The mean Glasgow Coma Scale score for
these patients was 5.1 points (range, 3 to 8 points), and the
mean Abbreviated Injury Scale score was 3.4 points (range, 2
to 5 points). The radiographic findings included subdural,
epidural, and subarachnoid hemorrhage as well as shearing
injuries and generalized brain edema.
All patients with an isolated bone fracture had sustained
a fracture of the shaft of the femur (eight patients) or tibia (six
patients). The long-bone fractures were imaged with conventional
anteroposterior and lateral radiographs. Clinical and radio-
graphic investigation revealed that none of the patients with
a long-bone fracture had sustained a traumatic brain injury.
Exclusion criteria included all forms of prior nervous system or
bone-related disease, immunosuppression, rheumatoid arthri-
tis, and diabetes as well as steroid or bisphosphonate therapy.
Blood samples were collected from all patients at four
time points during the first week following the injury. The
first sample was obtained as soon as possible after hospital
admission but always within six hours after the injury. Sub-
sequent samples were collected at twenty-four, seventy-two,
and 168 hours after the injury. All specimens (except the first
sample after the injury) were obtained at approximately 8:00
A.M. in order to reduce the circadian influence on biochemical
markers and to maintain similar conditions in all groups.
Samples were centrifuged at 1500 times gravity for ten minutes
within thirty minutes after collection, and the resulting serum
was stored at 280C. The levels of alkaline phosphatase, ad-
justed calcium, inorganic phosphate, and parathyroid hor-
mone were measured in all collected samples.
All patients were followed clinically for a minimum of
twelve months after discharge. Clinical and radiographic as-
sessments of heterotopic ossification (defined as ectopic bone
in the muscle and connective tissue surrounding joints) were
performed.
Isolation and Culture of Human Skeletal Muscle Cells
Isolation of cells from skeletal muscle was performed on the
basis of previously described methods for obtaining primary
skeletal muscle cell cultures29-32. Briefly, muscle samples (ap-
proximately 1 cm3) were excised intraoperatively and trans-
ported in 0.9% saline solution. Muscle samples from different
patients were not pooled. Samples were digested in 0.05%
trypsin-EDTA (GIBCO Invitrogen, Auckland, New Zealand)
for one hour, and the supernatant was centrifuged at 1200 rpm
for eight minutes. The resultant cell pellet was redistributed
into 25-cm2 culture flasks (Sarstedt, Nu¨mbrecht, Germany)
containing standard medium consisting of 5 mL of Dulbecco
modified Eagle medium/Ham F-12 (DMEM/F12; GIBCO
Invitrogen), 15% fetal calf serum (JRH Biosciences, a division
of SAFC Biosciences, Lanoxa, Kansas), and 1% antibiotic-
antimycotic liquid (10,000 U/mL of penicillin-G sodium,
10,000 mg/mL of streptomycin sulfate, and 25 mg/mL of am-
photericin B; GIBCO Invitrogen). Cells were incubated at
37C with 5% CO2. The medium was changed weekly. When
they approached confluence, cells were passaged by trypsini-
zation and redistribution into new flasks. Characterization was
performed within the first three passages, and further experi-
mentation was carried out within three passages after charac-
terization. Cells were tested in multiple experiments with serum
from different subjects.
Immunohistochemical Characterization of
Human Skeletal Muscle Cells
Cells were fixed in 1% paraformaldehyde in 0.1M phosphate-
buffered saline solution (GIBCO Invitrogen), pH 7.2, and
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permeabilized in 0.1% Triton X-100 (Sigma-Aldrich, St. Louis,
Missouri). They were then exposed to primary monoclonal
antibodies for alkaline phosphatase (hybridoma cell superna-
tant [B4-78], Mayo Clinic, Rochester, Minnesota), desmin
(1:200, DE-U-10 clone; Sigma-Aldrich), and vimentin (1:200,
VIM-13.2 clone; Sigma-Aldrich), followed by a donkey anti-
mouse Alexa Fluor 488 secondary antibody (1:50; Molecular
Probes, Eugene, Oregon). Counterstaining was performed
with DAPI (49,6-diamidino-2-phenylindole-dihydrochloride)
(1:1000; F. Hoffmann-La Roche, Basel, Switzerland) and Alexa
Fluor 546 phalloidin (1:100; Molecular Probes). SYTO 25
green fluorescent nucleic acid stain (1:1000; Molecular Probes)
was used as a nuclear stain in live cells.
Isolation and Culture of Human Peripheral
Blood Monocytic Cells and T-Lymphocytes
Human monocytic cells and T-lymphocytes were obtained
from peripheral blood mononuclear cells isolated from buffy
coats of healthy blood donors (Australian Red Cross Blood
Service [ARCBS], Perth, Western Australia, Australia) through
Ficoll-gradient centrifugation (Amersham Biosciences, Upp-
sala, Sweden). The isolated peripheral blood mononuclear cells
were cultured (37C, humidified, 5% CO2) in 25-cm2 tissue-
culture flasks (Sarstedt) in RPMI-1640 GlutaMAX medium
(GIBCO Invitrogen), supplemented with 5% human serum
(ARCBS) and 1% antibiotic-antimycotic liquid. After one hour
in culture, the nonadherent peripheral blood mononuclear
cells (95% of which were T-lymphocytes) were collected and
washed twice with phosphate-buffered saline solution before
being processed further as described below. The cultures of
adherent cells (95% of which were monocytic cells) were gently
washed three times with 10 mL of phosphate-buffered saline
solution at room temperature and replenished with 5 mL of
fresh RPMI-1640 GlutaMAX medium supplemented with 1%
antibiotic-antimycotic liquid. Thereafter, the cells were gently
scraped from the flasks and used as described below. Ethical
approval for using human blood cells for this study was granted
by the Ethics Committee of the University of Western Australia
and the ARCBS.
Assessment of Proliferation of Human Skeletal Muscle Cells
The colorimetric CellTiter 96 MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl-tetrazolium bromide) assay (Promega, Madison,
Wisconsin) was used to assess the effect of serum collected
from the different study groups on the proliferation rates of
human skeletal muscle cells. Muscle cells were suspended in
ninety-six-well plates (Sarstedt) at 5 · 104 cells/mL of medium
(DMEM/F12, 1% antibiotic-antimycotic liquid) and 6.25%
serum from the different study groups. After five days, 20 mL
of the assay reagent was added to each well. Proliferation was
assessed between the fifth and sixth days during the log phase
of growth. The plates were read and recorded with use of a
scanning multiwell spectrophotometer (Multiskan RC; Lab-
systems, Helsinki, Finland) at an absorbance of 405 nm.
Additionally, in order to investigate the specificity of the
proliferative effect of serum on skeletal muscle cells, proliferation
assays were performed with non-muscle-derived cells. Briefly,
5 · 105 T-lymphocytes or monocytic cells were seeded in
round-bottom ninety-six-well plates (Sarstedt) with 200 mL
of RPMI-1640 GlutaMAX medium supplemented with 1%
antibiotic-antimycotic liquid per well. Serum from the dif-
ferent study groups was added at a concentration of 6.25%
(12.5 mM). All proliferation assays with T-lymphocytes were
carried out with phytohemagglutinin (5 mL/well) activation.
Cell proliferation was measured after five days of incubation
with use of a cell proliferation enzyme-linked immunosorbent
assay (ELISA) 5-bromo-29-deoxyuridine (BrdU) colorimetric
kit (F. Hoffmann-La Roche), according to the manufacturer’s
instructions. The plates were read and recorded with use of
a scanning multiwell spectrophotometer (Multiskan RC) at an
absorbance of 405 nm. Data were subsequently expressed as the
percentage of absorbance relative to the absorbance of the cells
isolated from the same individual and incubated without serum
during the same period of time.
Western Blot Analysis
Western blot analysis was used to detect cell expression of
Osterix protein. Near confluence, the standard medium was
replaced with serum-free medium for twenty-four hours, and
then 5% serum from the traumatic brain injury or control group
was added. After one week, cells were lysed with a whole-cell
lysate buffer. A 12% sodium dodecyl sulfate polyacrylamide gel
was used for two-dimensional protein separation. Twenty-five
microliters of protein was loaded into each well, and electro-
phoresis was performed at 100 to 150 V. Proteins were trans-
ferred to nitrocellulose membranes (Amersham Biosciences),
and excess antigens were blocked with 5% milk for thirty min-
utes. Membranes were incubated with 1:500 primary antibody
(goat polyclonal anti-Osterix [Santa Cruz Biotechnology, Santa
Cruz, California]; and mouse monoclonal anti-actin [Sigma-
Aldrich]) overnight at 4C. For Osterix, a biotinylated donkey
anti-goat secondary antibody (1:1000; Santa Cruz Biotech-
nology) was used for one hour at room temperature. Mem-
branes were then incubated with a horseradish peroxidase
conjugated goat anti-rabbit IgG (1:10,000; Dako, Glostrup,
Denmark) for one hour at room temperature. SuperSignal
West Pico reagents (Pierce Biotechnology, Rockford, Illinois)
were added to the membrane for five minutes, and signals were
visualized on a Kodak 2000MM Imaging System (Kodak,
Rochester, New York). After stripping, b-actin was used as an
internal positive control. Human fetal osteoblasts (hFOB 1.19;
American Type Culture Collection, Manassas, Virginia) cul-
tured in standard medium were used to ensure antibody
specificity.
Mineralization and Alkaline Phosphatase Activity
Cells were suspended in six-well plates (Sarstedt) containing
standard medium. At confluence, the standard medium was
replaced with serum-free medium. After twenty-four hours, a
mineralization medium (DMEM/F12, 1% antibiotic-antimycotic
liquid, 2mM b-glycerophosphate, and 12.5 mg/mL of ascor-
bic acid) and 5% serum from the traumatic brain injury or
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control group were added. The medium was changed every
five days, and the supernatant was collected for measurement
of alkaline phosphatase activity. Supernatants were analyzed
with the Roche Hitachi 917 analyzer (Roche Diagnostics,
Rotkreuz, Switzerland), which employs a spectrophotometer
to determine alkaline phosphatase activity on the basis of the
production of p-nitrophenol. After three weeks, cells were
fixed in 70% ethanol and the Villanueva osteochrome bone
stain (Polysciences Europe, Eppelheim, Germany) was per-
formed in situ. One milliliter of reagent was added to each well,
and, after ninety minutes, the cells were washed with distilled
water and 70% ethanol until the wash solution was colorless.
The nodules in each well were counted and averaged over three
plates.
Statistical Analysis
A two-way repeated-measures analysis of variance was used to
test mean differences between the study groups in terms of cell
proliferation rates and in terms of serum marker concentrations.
Independent-samples t tests were used to determine specific
differences according to group and the time point after injury.
Pearson correlations (bivariate) were used to analyze the con-
tinuous variables, including patient age, proliferation rate,
Glasgow Coma Scale score, Abbreviated Injury Scale score, and
serum marker concentrations. A p value of <0.05 was con-
sidered significant.
Source of Funding
There was no external funding source for this study.
Fig. 1
The adult human skeletal muscle cell populations contained two main morphological
types: elongated, multinucleated cells and spindle-shaped cells (A). Myotubes
stained positive for desmin (B). The majority of the fibroblastic cells were positive for
vimentin (green) (C) and actin (red) (D), while some were positive for alkaline
phosphatase (blue) (E). DAPI-stained nuclei are blue or red (F). The images represent
experiments on at least three different cell lines. Bar = 20 mm.
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Results
Biochemical Markers and Clinical Assessment of
Heterotopic Ossification
There were no significant differences in serum alkalinephosphatase, phosphate, or parathyroid hormone con-
centrations between the groups at any time point (p > 0.05).
The serum calcium levels in the patients with a traumatic brain
injury were significantly lower than those in the patients with
an isolated long-bone fracture or the control patients across all
time points (p < 0.05). Radiographic evidence of heterotopic
ossification was found in four of the thirteen patients with an
isolated traumatic brain injury. None of the patients with an
isolated long-bone fracture revealed evidence of heterotopic
ossification on clinical or radiographic follow-up.
Skeletal Muscle Cell Characterization
The thirty-eight primary skeletal muscle cell cultures were
tested for expression of myogenic genes with use of reverse
transcription-polymerase chain reaction. All cell cultures ex-
pressed myosin heavy chain IIa (MyHCIIa). Additionally,
morphological methods were used for further cell characteri-
zation. Cell populations consisted primarily of two cellular
morphologies: elongated, multinucleated cells (skeletal muscle
fibers) and spindle-shaped cells (precursor cells). Immuno-
histochemical staining was used to visualize specific markers
within the skeletal muscle cell population. The myogenic
tendency of the cell populations was demonstrated by desmin
staining of elongated cells containing multiple nuclei, consis-
tent with myotubes. The stromal nature of the spindle-shaped
cell population was exemplified by the high degree of positive
staining for vimentin. Some spindle-shaped cells constitutively
stained positive for alkaline phosphatase (Fig. 1).
Serum from Patients with Severe Traumatic Brain Injury
Enhances Muscle Cell Proliferation
One of the aims of this study was to investigate the effects of
serum from patients with traumatic brain injury on the pro-
liferation rates of cells extracted from human skeletal muscle.
The first step was to evaluate whether the age of the muscle
donor influenced cell proliferation. For that purpose, human
skeletal muscle cells isolated from ten donors with a wide
range of ages (eighteen to eighty years) were exposed to the
same serum collected from either patients with traumatic
brain injury or controls (three samples per group). With the
numbers studied, the investigations revealed no significant
age-dependent differences in the proliferation rates of skeletal
muscle cells exposed to serum in vitro (p > 0.05). Conse-
quently, the range of ages of the muscle donors was not re-
stricted. The time after injury did not affect muscle cell
proliferation within the first three days (p > 0.05). However,
analysis showed a maximum of activity that was slightly, but
Fig. 2
The mean proliferation rates (and standard error) of skeletal muscle cells
measured after exposure to sera (6.25%, collected at twenty-four hours
after injury) from the study groups. All thirty-seven serum samples were
tested in five cell cultures. The data are expressed as the percentage of
absorbance relative to the absorbance of the cells isolated from the same
individual and incubated without serum during the same period of time.
*Cells incubated with serum collected from patients with a severe trau-
matic brain injury (TBI) had a significantly higher proliferation rate (p = 0.02).
Fig. 3
Nonquantitative Western blot with Osterix antibody. Lane 1 represents cells
treated with serum from a patient with a traumatic brain injury (TBI). Lane 2
represents cells treated with control serum. Lane 3 is a serum-free negative
control. Lane 4 is a positive control consisting of the osteoprogenitor cell line
hFOB 1.19. The expected product is approximately 45 kDa. The 50-kDa molecular
weight marker is indicated. A Western blot for b-actin protein is shown in the
bottom row.
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not significantly, greater than the earlier level at twenty-four
hours after injury, with the activity remaining at the same
level for three days before declining one week after the injury.
As a result, the serum samples collected at twenty-four hours
after the injury were chosen for all subsequent experiments.
All thirty-seven serum samples were tested for their prolif-
eration potential in five primary muscle cell cultures as well as
in five cultures of human T-lymphocytes and monocytic
cells collected from five different donors. Repeated-measures
analysis of variance showed no significant difference in pro-
liferation between the cells from different donors cultured
in the presence of the same serum (p = 0.42). Each of the
thirty-eight muscle specimens was exposed to each type of
serum.
The mean proliferation rate of the skeletal muscle cells
exposed to serum from patients with severe traumatic brain
injury (1.87 [95% confidence interval, 1.66 to 2.09]) was sig-
nificantly greater (p = 0.02) than the proliferation rates of cells
exposed to serum from patients with a long-bone fracture
(1.42 [95% confidence interval, 1.21 to 1.58]) and from con-
trol subjects (1.35 [95% confidence interval, 1.15 to 1.54])
(Fig. 2). The serum from patients with a traumatic brain
injury did not increase the proliferation rates of human T-
lymphocytes or monocytic cells when compared with the se-
rum from patients with an isolated fracture or that from
controls (p > 0.05).
Serum Supports an Increase in Alkaline
Phosphatase Activity
Alkaline phosphate activity was measured in the culture su-
pernatant of five primary muscle cell lines cultured in the
presence or absence of normal serum and traumatic brain
injury-group serum that had induced the highest rate of
muscle cell proliferation. Both the cell populations treated
with serum from the traumatic brain injury group and
those treated with the control serum exhibited an increase
in alkaline phosphatase activity over the duration of the
experiments. A significant difference in alkaline phospha-
tase activity was found between both study groups and
the serum-free negative control (p < 0.05), but there was
no significant difference between the serum-treated groups
(p = 0.20).
Fig. 4
The spindle-shaped cell population proliferated and formed cellular condensations in
response to serum (A). Villanueva staining of muscle cells demonstrated small
numbers of positive-staining nodules after three weeks of culture in mineralization
medium and serum from the traumatic brain injury or control group (B and C), with no
significant difference in the number of nodules between the two groups (p > 0.05).
There was no evidence of nodule formation by untreated cells (D).
650
TH E J O U R N A L O F B O N E & JO I N T SU R G E RY d J B J S . O R G
VO LU M E 92-A d NU M B E R 3 d M A R C H 2010
SE R U M A F T E R BR A I N IN J U RY IN C R E A S E S MU S C L E CE L L
PR O L I F E R AT I O N , SU P P O R T S OS T E O B L A S T MA R K E R EX P R E S S I O N
Serum Supports Osterix Protein Expression
Osterix expression was measured as a late osteoblastic differ-
entiation marker. For that purpose, five different primary
muscle cell lines were cultured in the presence or absence of at
least three different samples of serum from both the traumatic
brain injury group and the control group. Western blot anal-
ysis revealed a band at the expected molecular weight (45 kDa)
for the Osterix protein in the serum-treated groups but not in
the serum-free negative controls, indicating the induction of
Osterix expression by human sera from both groups. Lanes
containing protein from hFOB 1.19 cells cultured in standard
medium containing 15% fetal calf serum showed the same
band (Fig. 3).
Serum Supports Mineralization of Skeletal Muscle Cells
Formation of bone nodules and production of calcified extra-
cellular matrix was tested with five primary muscle cell cultures
in the presence of the traumatic brain injury-group serum that
had induced the highest rate of muscle cell proliferation and
in the presence of control serum. Villanueva staining of the
skeletal muscle cells after three weeks of culture in a miner-
alization medium showed frequent condensations of spindle-
shaped cells and small numbers of positively stained nodules
arising from spindle-shaped cells in the serum-treated groups;
these findings were not present in the untreated negative
controls (Fig. 4). At least two of three plates for both serum
study groups contained Villanueva-positive nodules. The mean
numbers of Villanueva-positive nodules (and the standard
deviation) per well were 1.7 ± 2.1 and 1 ± 1 in the traumatic
brain injury group and the normal control group, respectively.
There was no significant difference in the number of nodules
between the two serum groups (p > 0.05).
Discussion
We previously demonstrated that patients with a traumaticbrain injury and a femoral shaft fracture have enhanced
fracture-healing, with a twofold shorter time to union and
increased callus formation compared with patients with a
femoral fracture but no traumatic brain injury 13. Proteomic
investigations have demonstrated a change in the profile of
serum and cerebrospinal fluid proteins in response to trau-
matic brain injury that is potentially linked to the osteogenic
influence that traumatic brain injury has on fracture-healing33.
Additionally, serum from subjects with a traumatic injury to
the central nervous system has been shown to increase the
proliferation and alkaline phosphatase expression of mesen-
chymal and osteoblastic cells. Bidner et al.11 showed that sera
from patients with a traumatic brain injury increased fetal rat
calvarial cell proliferation compared with that induced by sera
from a group without a traumatic brain injury. Boes et al.12
found that pooled sera from rats with a traumatic brain injury
and a fracture increased proliferation of mesenchymal stem
cells, but not fibroblastic or osteoblastic cell lines, compared
with that induced by sera from rats with a fracture alone. Sera
from rats with a traumatic brain injury have also been shown
to increase alkaline phosphatase activity in rat bone-marrow
stromal cells15. Taken together, these results strongly support
the concept that osteoinductive factors are released by the
injured brain into the systemic blood circulation and subse-
quently act peripherally on the affected soft tissues. The same
humoral factors may also be implicated in the development
of heterotopic ossification within skeletal muscle following a
traumatic brain injury. It has been suggested that the consol-
idated callus that has been observed in patients with traumatic
brain injury is a form of local heterotopic bone formation34,35.
This suggestion has been supported by the histological finding
that callus at the sites of fractures in patients with a traumatic
brain injury more closely resembles heterotopic bone than
normal fracture callus36.
The osteogenic capability of skeletal muscle cell popu-
lations was suggested by the constitutive high levels of alkaline
phosphatase at the protein and functional level. Alkaline
phosphatase is thought to be required for the release of inor-
ganic phosphate into the osseous matrix37, but it is also a rel-
atively early marker of osteoblastic lineage that can be used to
assess the osteogenic potential of clonal populations of os-
teoprogenitors23,38,39. Interestingly, it has been detected in in-
tramuscular connective tissue40. During extended culture, the
alkaline phosphatase activity within the serum-treated muscle
cell populations increased significantly in our study, empha-
sizing the growth-promoting effects of serum on cells ex-
pressing functional alkaline phosphatase. Kurer et al.16 showed
that serum both from patients with a spinal cord injury and
control volunteers increased the alkaline phosphatase activity
in cells extracted from human femora. Klein et al.15 also
demonstrated an increase in alkaline phosphatase activity in
rat bone-marrow stromal cells exposed to serum obtained
from rats after traumatic brain injury.
Untreated skeletal muscle cell populations in our study
did not show evidence of Osterix protein expression, which is
consistent with an immature state of osteoblastic differentia-
tion. Osterix is specific to the osteoblastic lineage, being found
only within the bone matrix, the endosteum, and the
periosteum postnatally41. Mice lacking Osterix have a complete
absence of osteoblasts, a finding that emphasizes its impor-
tance in the commitment of osteoprogenitor cells to become
mature osteoblasts42,43. Skeletal muscle cells cultured with se-
rum from both experimental groups in our study showed
evidence of induction of Osterix protein and generated min-
eralized nodules. These findings imply that sera from normal
individuals and those with traumatic brain injury contain
factors capable of supporting osteoblastic maturation and
mineralization by putative skeletal muscle osteoprogenitors
in vitro.
Mineralized nodules arose from vimentin-positive
spindle-shaped cells, as opposed to cells with the myotube
morphology, implying that cells involved in ossification within
skeletal muscle cells in vitro might lie external to the myofiber.
The expression of vimentin is associated with the mesenchy-
mal phenotype, including fibroblasts and skeletal muscle
stem cells21. Some of the spindle-shaped cells present in skel-
etal muscle have been linked to mesenchymal stem cells,
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bone-marrow stromal cells, and pericytes because of their
similar morphological, immunohistochemical, and mRNA pro-
files and their capacity for multilineage differentiation22,23,28,44.
The involvement of the skeletal muscle interstitium in hetero-
topic ossification has been suspected for decades45-50. The central
role of mesenchymal cells from skeletal muscle connective tissue
in the development of heterotopic ossification following trauma
to the central nervous system is supported by histological analysis
of ossific deposits.
The results of this study indicate a relationship between
severe traumatic brain injury and serum-induced proliferation
of skeletal muscle cells. Widespread DNA synthesis throughout
the proliferated cell cultures was detected predominantly in
isolated nuclei or aggregations of nuclei, a finding consistent
with bright-field observations of increased fibroblastic cell
numbers and the formation of cellular condensations. It is
plausible that the additional proliferative effect of serum fac-
tors present after severe traumatic brain injury on skeletal
muscle mesenchymal and early osteoblastic cells shifts the
balance toward the development of bone in a tissue in which
bone is not normally found. This proliferative effect may be
essential for the development of heterotopic ossification in
these patients because it produces an excess of cells with os-
teogenic potential within soft tissues. The finding that serum
taken at six, twenty-four, or seventy-two hours after traumatic
brain injury induced similar mean proliferation rates suggests
that the processes underlying the observed serum-mediated
proliferation begin at least as early as six hours after injury and
continue at a relatively constant rate throughout the first three
days after injury. n
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